Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

G. Borthakur, Jörge E. Cortes(The University of Texas MD Anderson Cancer Center)
Haematologica
October 15, 2010
10.3324/haematol.2010.030452
Cited by 204

Related Papers

Third-line therapy for chronic myeloid leukemia: current status and future directions
|Journal of Hematology & Oncology|2021|115
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
|Haematologica|2015|58